GlassScriptPhysician profile
Willie M Talbert
NPI 1356833420
$1,580.59
in general payments reported to CMS, 2019-2025
17 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.12 · 2022: $580 · 2023: $780 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $356.23 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Merz North America, INC. | $314.04 | 2023-2025 | Xeomin |
| Novartis Pharmaceuticals Corporation | $257.56 | 2022-2023 | |
| Glaxosmithkline, LLC. | $170.22 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $158.53 | 2022-2023 | |
| Pfizer INC. | $62.14 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $44.60 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Jazz Pharmaceuticals INC. | $37.95 | 2023 | |
| Abbvie INC. | $36.50 | 2022-2023 | Linzess |
| Xeris Pharmaceuticals, INC. | $35.46 | 2021-2023 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.02 | 2023 | |
| Novo Nordisk INC | $16.08 | 2023 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $15.57 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $14.77 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $14.34 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $12.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Talbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.